Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development

被引：130

作者：

Costa, Ricardo ^{[1
]}

Shah, Ami N. ^{[3
]}

Santa-Maria, Cesar A. ^{[1
,2
]}

Cruz, Marcelo R. ^{[1
]}

Mahalingam, Devalingam ^{[4
,5
,6
]}

Carneiro, Benedito A. ^{[1
,2
]}

Chae, Young Kwang ^{[1
,2
]}

Cristofanilli, Massimo ^{[1
,2
]}

Gradishar, William J. ^{[1
,2
]}

Giles, Francis J. ^{[1
,2
]}

机构：

[1] Feinberg Sch Med, Div Hematol Oncol, Dev Therapeut Program, Chicago, IL USA

[2] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[3] Feinberg Sch Med, Div Hematol Oncol, Chicago, IL USA

[4] Univ Texas Hlth Sci Ctr San Antonio, Dept Med Canc Res, San Antonio, TX 78229 USA

[5] Univ Texas Hlth Sci Ctr San Antonio, Therapy Ctr, San Antonio, TX 78229 USA

[6] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, San Antonio, TX 78229 USA

来源：

CANCER TREATMENT REVIEWS | 2017年 / 53卷

关键词：

Triple negative breast cancer; Epidermal Growth Factor Receptor; Targeted therapy; mTOR; CELL LUNG-CANCER; IXABEPILONE PLUS CAPECITABINE; PATHOLOGICAL COMPLETE RESPONSE; MONOCLONAL-ANTIBODY CETUXIMAB; RANDOMIZED PHASE-II; 1ST-LINE TREATMENT; OPEN-LABEL; PROTEIN EXPRESSION; CLINICAL-PRACTICE; SPORADIC BREAST;

D O I：

10.1016/j.ctrv.2016.12.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Triple negative breast cancer (TNBC) accounts for 10-20% of cases in breast cancer. Despite recent advances in the treatment of hormonal receptor+ and HER2+ breast cancers, there are no targeted therapies available for TNBC. Evidence supports that most patients with TNBC express the transmembrane Epidermal Growth Factor Receptor (EGFR). However, early phase clinical trials failed to demonstrate significant activity of EGFR-targeted monoclonal antibodies and/or tyrosine kinase inhibitors. Here, we review the recent discoveries related to the underlying biology of the EGFR pathway in TNBC, clinical progress to date and suggest rational future approaches for investigational therapies in TNBC. (C) 2017 Elsevier Ltd. All rights reserved.

引用

页码：111 / 119

页数：9

共 113 条

[1] ALI SM, 2015, SAN ANT BREAST CANC
[2] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, Stephen M.
Lesokhin, Alexander M.
Borrello, Ivan
Halwani, Ahmad
Scott, Emma C.
Gutierrez, Martin
Schuster, Stephen J.
Millenson, Michael M.
Cattry, Deepika
Freeman, Gordon J.
Rodig, Scott J.
Chapuy, Bjoern
Ligon, Azra H.
Zhu, Lili
Grosso, Joseph F.
Kim, Su Young
Timmerman, John M.
Shipp, Margaret A.
Armand, Philippe
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) : 311 - 319
[3] A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair
Ashworth, Alan
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) : 3785 - 3790
[4] Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma
Baldassarre, G
Battista, S
Belletti, B
Thakur, S
Pentimalli, F
Trapasso, F
Fedele, M
Pierantoni, G
Croce, CM
Fusco, A
[J]. MOLECULAR AND CELLULAR BIOLOGY, 2003, 23 (07) : 2225 - 2238
[5] Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer
Barrett, Michael T.
Anderson, Karen S.
Lenkiewicz, Elizabeth
Andreozzi, Mariacarla
Cunliffe, Heather E.
Klassen, Christine L.
Dueck, Amylou C.
McCullough, Ann E.
Reddy, Srikanth K.
Ramanathan, Ramesh K.
Northfelt, Donald W.
Pockaj, Barbara A.
[J]. ONCOTARGET, 2015, 6 (28) : 26483 - 26493
[6] ANTITUMOR EFFECTS OF DOXORUBICIN IN COMBINATION WITH ANTIEPIDERMAL GROWTH-FACTOR RECEPTOR MONOCLONAL-ANTIBODIES
BASELGA, J
NORTON, L
MASUI, H
PANDIELLA, A
COPLAN, K
MILLER, WH
MENDELSOHN, J
[J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (16) : 1327 - 1333
[7] Randomized Phase II Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer
Baselga, Jose
Gomez, Patricia
Greil, Richard
Braga, Sofia
Climent, Miguel A.
Wardley, Andrew M.
Kaufman, Bella
Stemmer, Salomon M.
Pego, Antonio
Chan, Arlene
Goeminne, Jean-Charles
Graas, Marie-Pascale
Kennedy, M. John
Ciruelos Gil, Eva Maria
Schneeweiss, Andreas
Zubel, Angela
Groos, Jutta
Melezinkova, Helena
Awada, Ahmad
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (20) : 2586 - +
[8] Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Baselga, Jose
Campone, Mario
Piccart, Martine
Burris, Howard A., III
Rugo, Hope S.
Sahmoud, Tarek
Noguchi, Shinzaburo
Gnant, Michael
Pritchard, Kathleen I.
Lebrun, Fabienne
Beck, J. Thaddeus
Ito, Yoshinori
Yardley, Denise
Deleu, Ines
Perez, Alejandra
Bachelot, Thomas
Vittori, Luc
Xu, Zhiying
Mukhopadhyay, Pabak
Lebwohl, David
Hortobagyi, Gabriel N.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (06) : 520 - 529
[9] Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, Jose
Cortes, Javier
Kim, Sung-Bae
Im, Seock-Ah
Hegg, Roberto
Im, Young-Hyuck
Roman, Laslo
Pedrini, Jose Luiz
Pienkowski, Tadeusz
Knott, Adam
Clark, Emma
Benyunes, Mark C.
Ross, Graham
Swain, Sandra M.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (02) : 109 - 119
[10] Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach
Beger, C
Pierce, LN
Krüger, M
Marcusson, EG
Robbins, JM
Welcsh, P
Welch, PJ
Welte, K
King, MC
Barber, JR
Wong-Staal, F
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (01) : 130 - 135

← 1 2 3 4 5 6 7 8 9 10 →